2. Company Profile A fast growing, fully integrated, research oriented pharmaceutical company with a Global presence Revenues in FY 2013-14 ` 7277 Mn (US $ 121 Mn) Domestic business contributes 64% and international business contributes 36% of the revenues Formulation business contributes 93% and API business contributes 7% of revenues Workforce of over 4500 - 200 R&D scientists - 2300 field staff

3. Our Infrastructure Corporate Office at Santacruz (E), Mumbai 8 Manufacturing Facilities - 5 FDFs - 3 APIs R&D Centre at Navi Mumbai 29 C&Fs

4. Mfg. Facilities for FDFs LOCATIONDOSAGE FORMAPPROVALS GOA I TABLETS, CREAMS & OINTMENTS US-FDA, EU-GMP, TGA Australia, MCC South Africa, ANVISA - Brazil GOA IISTERILE PRODUCTS US-FDA, EU-GMP, MCC South Africa, TGA Australia GOA IIITABLETS US-FDA, EU-GMP, TGA Australia, WALUJTABLETSEmerging Markets BADDI TABLETS, LIQUID ORALS & TOOTHPASTES EU–GMP and Emerging Markets

5. API facilities Multi-ton : Patalganga (USFDA, TGA Australia approved) - Reactor Capacity: 500 to 5000 L Kilo Scale: Navi Mumbai (USFDA, TGA Australia approved) - Reaction Systems: 16 to 500 L - Total Reactor Volume: 1 cubic meters - Temperatures range: -55 to + 150 celsius Intermediates : Rabale - Reactor Capacity: 500 to 3000 L - Total Reactor Volume: 50 cubic meters

6. Research & Development US $ 10 Mn Investment in R&D set-up Spread over an area of 150,000 square feet and employs over 200 scientists and technical personnel 58 Patents filed - 38 for APIs - 20 for FDFs

7. Business Model Branded Generics - 8 Marketing Divisions - 18 Therapeutic Segments - 150 Brands APIs Regulated Markets - Generic Business - CRAMS - Alliances Emerging Markets - Branded Generics - Through Distributors - Alliance

8.  Ranked 27th by CMARC in Rx Ranking  Ranked 28th by AWACS in SSA Audit (Sept’14) 8 MARKETING DIVISIONS INDOCO GPs, CPs, Gynaec, Pediatrician SPADE GPs, CPs, Pediatrician, ENTs, Otologicals WARREN Dental EXCEL Opthalmic SPERA GPs, Gynaec, Pediatrician ETERNA CPs, Orthos, Gastro INDOCO CND Lifestyle / Cardio & Diabetology INSTITUTION Caters to Hospital & Government Supplies Indian Business

9. Growth Drivers (Domestic Business) Growing middle class population, increasing income levels, rapid urbanization, demand for quality healthcare services & changing lifestyle Focus on chronic segment Penetration in Northern and Eastern Regions New Products introductions (around 20 products every year) Growth above Industry Average

10. International Business Revenue of Rs. 2005 Mn in FY14 (US $ 33 Mn) Revenue contribution UK 48%, USA 23 %, SA 12%, Germany 8%) CRAMS, Dossier Out-Licensing, Out-Licensing of MAs Actavis (Watson) Partnership Regulated Markets (85% of Formulation Export Business) Revenue of Rs. 307 Mn in FY14 (US $ 5 Mn) Revenue contribution Africa 8%, Asia 2%, Latam 2% Promotion of Branded Generics through Distributors Aspen Partnership Emerging Markets (15% of Formulation Export Business)

11. Strong Partnership with Watson Pharmaceuticals Inc., USA Multi-product, Multi-territory alliance with Aspen Pharmacare, SA Own filing of ANDAs and Dossiers NDDS and new technology platforms Growth Drivers (International Business)

12. Segment wise Break-up and Contribution

13. (` In Lacs) Profit & Loss A/C – Percentage to Net Sales Particulars Quarter Ended Half Year Ended Year Ended 31.03.14 (Audited) % to Sales 30.09.14 (Unaudited) % to Sales 30.09.13 (Unaudited) % to Sales 30.09.14 (Unaudited) % to Sales 30.09.13 (Unaudited) % to Sales INCOME Net Sales / Income from Operations 22642 19505 42437 34310 71737 Add: Other Operating Income201 726 269 1318 1034 Total Income from Operations 22843 20231 42706 35628 72771 Add: Other Income56 46 118 62 175 Total Income22899 20277 42824 35690 72946 EXPENDITURE Material Cost797135.2757638.81522835.91354539.52691637.5 Employees Benefit Expenses359615.9333817.1697016.4622118.11290518.0 Research & Development Expenses 4892.23842.09182.26581.914432.0 Other Expenses592426.2563528.91107026.1946827.61950027.2 Finance Cost2681.25272.75411.311493.318802.6 Depreciation and Amortisation Expenses 13155.87724.022625.315054.430914.3 Misc. Expenditure Written Off. -- -- - -- 1 - Total Expenses19563 18232 36989 32546 65735 PBT333614.7204510.5583513.731449.2721110.1 Tax Expenses1095 441 1590 622 1421 PAT22419.916048.2424510.025227.457908.1 EBIDTA (w/o R&D)535223.6368218.9943822.2639418.61345118.8 EBIDTA (with R&D)486321.5329816.9852020.1573616.71200816.7 Operating Profit376916.7238312.2663515.6374010.9847911.8